Rexahn Pharmaceuticals, Inc. (nyse mkt:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and financial results for the quarter ended June 30, 2014. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) belongs to Healthcare sector. Its weekly performance is 2.86%. On last trading day company shares ended up $0.71. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) distance … Continue reading Shining on Major News: Rexahn Pharmaceuticals (NYSEMKT:RNN), Anadigics (NASDAQ:ANAD), Markit (NASDAQ:MRKT), Educational Development Corporation (NASDAQ:EDUC), Chindex International Inc. (NASDAQ:CHDX)